Cancer
ALISCA-Breast1
Breast Cancer
A Phase 2 study of alisertib in combination with endocrine therapy in patients with HR+, HER2- negative recurrent or metastatic breast cancer.
Contact Research Team:
[email protected]
Site principal investigator:
Timothy Pluard, MD
Learn more about this study:
NCT06369285